Scancell (LON:SCLP) Hits New 1-Year Low – What’s Next?

Scancell Holdings plc (LON:SCLP – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as GBX 78 and last traded at GBX 78, with a volume of 525,058 shares changing hands. The stock had previously closed at GBX 79.80.

Scancell Trading Down 2.3%

The company has a debt-to-equity ratio of -88.01, a quick ratio of 13.01 and a current ratio of 0.28. The stock’s fifty day moving average is GBX 91.78 and its 200 day moving average is GBX 130.21. The stock has a market cap of £105.82 million, a P/E ratio of -4.51 and a beta of 0.69.

Scancell (LON:SCLP – Get Free Report) last issued its quarterly earnings data on Friday, October 9th. The company reported GBX (17.30) earnings per share for the quarter. Scancell had a positive return on equity of 128.87% and a negative net margin of 116.98%. As a group, equities research analysts predict that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

Scancell Company Profile

(Get Free Report)

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.

Further Reading

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.